person · Reporting owner
Papapetropoulos Spyros
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lipocine Inc.LPCN · Entity 7696 | Director | June 04, 2025 | June 05, 2025 |
| Neuphoria Therapeutics Inc.NEUP · Entity 7639 | Director · President and CEO | August 27, 2025 | September 02, 2025 |
| Vigil Neuroscience, Inc.VIGL · Entity 11675 | Chief Medical Officer | November 18, 2022 | November 22, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lipocine Inc.
Report date June 04, 2025 · Filed June 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2035-06-04 | Direct | 7,174 |
Reported balance
After 2025-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-04 · Grant · Acquired 1,764 · Balance 7,174 F1: 100% vesting one year from date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% vesting one year from date of grant.
Neuphoria Therapeutics Inc.
Report date August 27, 2025 · Filed September 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right-to- Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 · Expires 2035-08-27 | Direct | 74,088 |
Reported balance
After 2025-08-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-08-27 · Grant · Acquired 34,559 · Balance 74,088 F1: Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a four-year period at the rate of 2.0833% of the shares of Common Stock on the last day of each month following August 1, 2025 until the options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a four-year period at the rate of 2.0833% of the shares of Common Stock on the last day of each month following August 1, 2025 until the options are fully vested.
Vigil Neuroscience, Inc.
Report date November 18, 2022 · Filed November 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,000 |
Ending reported balance
After 2022-11-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-11-18 · Exercise / conversion · Acquired 300 · Balance 4,300 Row 2 · 2022-11-18 · Sale · Disposed 300 · Balance 4,000 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. |
| Stock Option Grant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.89 · Expires 2030-11-18 | Direct | 149,604 |
Reported balance
After 2022-11-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-18 · Exercise / conversion · Disposed 300 · Balance 149,604 F2: 25% of the shares subject to this option vested and became exercisable on September 14, 2021, with the remainder vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022.
F2: 25% of the shares subject to this option vested and became exercisable on September 14, 2021, with the remainder vesting in 36 equal monthly installments thereafter.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Adamas Pharmaceuticals Inc
Report date November 24, 2021 · Filed November 24, 2021
Section 16 reporting ended · disclosed 2021-11-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 1
1 source rowRow 1 · 2021-11-24 · Other · Disposed 20,975 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price. F3: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.35 · Expires 2030-11-21 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-24 · Disposition to issuer · Disposed 20,000 · Balance 0 F6: $3.75 plus two CVRs per share underlying the stock option. F4: The shares subject to the option vest annually in equal installments over 3 years. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2031-06-01 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-24 · Disposition to issuer · Disposed 10,000 · Balance 0 F7: $2.89 plus two CVRs per share underlying the stock option. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price").
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price.
F3: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value.
F4: The shares subject to the option vest annually in equal installments over 3 years.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.
F6: $3.75 plus two CVRs per share underlying the stock option.
F7: $2.89 plus two CVRs per share underlying the stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2025 Filed Sep 2, 2025 11:02 UTC | Neuphoria Therapeutics Inc. NEUP · Entity 7639 | GrantEmployee Stock Option (Right-to- Buy) · Derivative | 34,559 | $8.27 Strike: $8.27 | $285,802.93 |
DisclosureSEC source: 0001213900-25-082904 · ownership.xml · derivative · entry 1 Papapetropoulos Spyros · CIK 0001832694 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,088 Underlying: Common Stock · 34,559 shares Expires 2035-08-27 F1 · derivative.exercise_date: Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a four-year period at the rate of 2.0833% of the shares of Common Stock on the last day of each month following August 1, 2025 until the options are fully vested. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:06 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 1,764 | $3.20 Strike: $3.20 | $5,644.80 |
DisclosureSEC source: 0001641172-25-013797 · ownership.xml · derivative · entry 1 Papapetropoulos Spyros · CIK 0001832694 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,174 Underlying: Common Stock · 1,764 shares Expires 2035-06-04 F1 · derivative.exercise_date: 100% vesting one year from date of grant. Read SEC document |
| April 16, 2025 Filed Apr 18, 2025 12:04 UTC | Neuphoria Therapeutics Inc. NEUP · Entity 7639 | GrantEmployee Stock Option (Right-to-Buy) · Derivative | 270,000 | $5.16 Strike: $5.16 | $1,393,200.00 |
DisclosureSEC source: 0001213900-25-033144 · ownership.xml · derivative · entry 1 Papapetropoulos Spyros · CIK 0001832694 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,529 Underlying: Common Stock · 270,000 shares Expires 2035-04-16 F1 · derivative.exercise_date: Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a three-year period at the rate of 2.78% of the shares of Common Stock on the last day of each month following September 1, 2024 until the options are vested. Read SEC document |
| April 16, 2025 Filed May 19, 2025 20:40 UTC Amendment | Neuphoria Therapeutics Inc. NEUP · Entity 7639 | GrantEmployee Stock Option (Right-to-Buy) · Derivative | 27,000 | $5.16 Strike: $5.16 | $139,320.00 |
DisclosureSEC source: 0001213900-25-045445 · ownership.xml · derivative · entry 1 Papapetropoulos Spyros · CIK 0001832694 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,529 Underlying: Common Stock · 27,000 shares Expires 2035-04-16 F1 · shares: The original Form 4, filed on April 17, 2025, is amended by this Form 4/A solely to correct a clerical error, which resulted in misreporting the number of derivative securities acquired (Item 5) and amount of securities underlying the derivative securities (Item 7) as 270,000 when the actual number of derivative securities acquired and amount of securities underlying the derivative securities was 27,000. With the correction of the clerical error, the number of derivative securities beneficially owned following the reported transaction (Item 9) is 39,529 shares. F2 · derivative.exercise_date: Subject to the Reporting Person's continuing service with the Company, the options shall vest on a monthly basis over a three-year period at the rate of 2.78% of the shares of Common Stock on the last day of each month following September 1, 2024 until the options are vested. F1 · derivative.underlying_shares: The original Form 4, filed on April 17, 2025, is amended by this Form 4/A solely to correct a clerical error, which resulted in misreporting the number of derivative securities acquired (Item 5) and amount of securities underlying the derivative securities (Item 7) as 270,000 when the actual number of derivative securities acquired and amount of securities underlying the derivative securities was 27,000. With the correction of the clerical error, the number of derivative securities beneficially owned following the reported transaction (Item 9) is 39,529 shares. F1 · balance_after: The original Form 4, filed on April 17, 2025, is amended by this Form 4/A solely to correct a clerical error, which resulted in misreporting the number of derivative securities acquired (Item 5) and amount of securities underlying the derivative securities (Item 7) as 270,000 when the actual number of derivative securities acquired and amount of securities underlying the derivative securities was 27,000. With the correction of the clerical error, the number of derivative securities beneficially owned following the reported transaction (Item 9) is 39,529 shares. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:48 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 1,764 | $7.05 Strike: $7.05 | $12,436.20 |
DisclosureSEC source: 0001493152-24-023215 · ownership.xml · derivative · entry 1 Papapetropoulos Spyros · CIK 0001832694 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,410 Underlying: Common Stock · 1,764 shares Expires 2034-06-05 F1 · derivative.exercise_date: 100% vesting one year from date of grant. Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:37 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.27 Strike: $0.27 | $7,968.00 |
DisclosureSEC source: 0001493152-23-016695 · ownership.xml · derivative · entry 1 Papapetropoulos Spyros · CIK 0001832694 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-10 F1 · derivative.exercise_date: 100% vesting one year from date of grant. Read SEC document |
| November 22, 2022 Filed Nov 28, 2022 21:33 UTC | Lipocine Inc. LPCN · Entity 7696 | PurchaseCommon stock | 21,739 | $0.47 | $10,217.33 |
DisclosureSEC source: 0001493152-22-033841 · ownership.xml · nonDerivative · entry 1 Papapetropoulos Spyros · CIK 0001832694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,739 Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 21:45 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | Exercise / conversionStock Option Grant (Right to Buy) · Derivative | 300 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0000899243-22-036831 · doc4.xml · derivative · entry 3 Papapetropoulos Spyros · CIK 0001832694 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,604 Underlying: Common Stock · 300 shares Expires 2030-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on September 14, 2021, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 21:45 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | SaleCommon Stock | 300 | $14.00 | $4,200.00 |
DisclosureSEC source: 0000899243-22-036831 · doc4.xml · nonDerivative · entry 2 Papapetropoulos Spyros · CIK 0001832694 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 21:45 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | Exercise / conversionCommon Stock | 300 | $1.89 | $567.00 |
DisclosureSEC source: 0000899243-22-036831 · doc4.xml · nonDerivative · entry 1 Papapetropoulos Spyros · CIK 0001832694 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 15:34 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.92 Strike: $0.92 | $20,240.00 |
DisclosureSEC source: 0001493152-22-016402 · ownership.xml · derivative · entry 1 Papapetropoulos Spyros · CIK 0001832694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 22,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: Subject to vesting whereby all of the shares subject to the award will vest on the one year anniversary of June 8, 2023. Read SEC document |
| May 03, 2022 Filed May 4, 2022 07:00 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | PurchaseCommon Stock | 4,000 | $3.40 | $13,591.20 |
DisclosureSEC source: 0000899243-22-016530 · doc4.xml · nonDerivative · entry 1 Papapetropoulos Spyros · CIK 0001832694 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.276 to $3.4059, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. Read SEC document |
| April 11, 2022 Filed Apr 12, 2022 21:00 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $1.16 Strike: $1.16 | $11,600.00 |
DisclosureSEC source: 0001493152-22-009718 · ownership.xml · derivative · entry 1 Papapetropoulos Spyros · CIK 0001832694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-04-11 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of April 11, 2023, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:05 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | GrantStock Option Grant (Right to Buy) · Derivative | 75,500 | $0.00 Strike: $16.13 | $0.00 |
DisclosureSEC source: 0000899243-22-009052 · doc4.xml · derivative · entry 1 Papapetropoulos Spyridon · CIK 0001832694 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,500 Underlying: Common Stock · 75,500 shares Expires 2032-03-01 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments, with the first installment vesting on April 1, 2022. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 16:09 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $5.21 | Not disclosed |
DisclosureSEC source: 0001328143-21-000089 · wf-form4_163778813188822.xml · derivative · entry 3 Papapetropoulos Spyridon · CIK 0001832694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2031-06-01 F7 · price: $2.89 plus two CVRs per share underlying the stock option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 16:09 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $4.35 | Not disclosed |
DisclosureSEC source: 0001328143-21-000089 · wf-form4_163778813188822.xml · derivative · entry 2 Papapetropoulos Spyridon · CIK 0001832694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2030-11-21 F6 · price: $3.75 plus two CVRs per share underlying the stock option. F4 · derivative.exercise_date: The shares subject to the option vest annually in equal installments over 3 years. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 16:09 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | OtherCommon Stock | 20,975 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001328143-21-000089 · wf-form4_163778813188822.xml · nonDerivative · entry 1 Papapetropoulos Spyridon · CIK 0001832694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price. F3 · price: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 16:16 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0001328143-21-000060 · wf-form4_162283774705681.xml · derivative · entry 2 Papapetropoulos Spyridon · CIK 0001832694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-01 F2 · derivative.exercise_date: The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 16:16 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001328143-21-000060 · wf-form4_162283774705681.xml · nonDerivative · entry 1 Papapetropoulos Spyridon · CIK 0001832694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,975 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 15:24 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | PurchaseCommon Stock | 5,975 | $5.06 | $30,233.50 |
DisclosureSEC source: 0001209191-21-020418 · doc4.xml · nonDerivative · entry 1 Papapetropoulos Spyridon · CIK 0001832694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,975 F1 · price: The shares were purchased at prices ranging from $4.85 to $5.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 22, 2020 Filed Nov 24, 2020 17:57 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Rightto Buy) · Derivative | 20,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001209191-20-060298 · doc4.xml · derivative · entry 2 Papapetropoulos Spyridon · CIK 0001832694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-11-21 F2 · derivative.exercise_date: The shares subject to the option vest annually in equal installments over 3 years. Read SEC document |
| November 22, 2020 Filed Nov 24, 2020 17:57 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-060298 · doc4.xml · nonDerivative · entry 1 Papapetropoulos Spyridon · CIK 0001832694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents the grant of restricted stock units that vest annually in equal installments over 3 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.